metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology OP-7 Further exploration of differences between lean and non-lean metabolic dysf...
Información de la revista
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Acceso a texto completo
OP-7 Further exploration of differences between lean and non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) in Latino subjects: PNPLA3 frequency and lipidomic profiles
Visitas
10
MARIA AYALA VALVERDE1, Jorge Arnold Alvarez1, Gustavo Ayares2, Francisco Barrera1, Daniel Cabrera1, Luis Antonio Diaz1, Juan Pablo Arab3, Ibon Martinez-Arranz4, Cristina Alonso4, Jesús M. Bañales5, Marco Arrese1
1 Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile, Chile
2 Pontificia Universidad Católica de Chile, Santiago, Chile
3 Virginia Commonwealth University School of Medicine, Richmond, VA (USA), Chile
4 OWL Metabolomics, Derio (Spain), Chile
5 Bioguipuzcoa Research Institute, San Sebastian (Spain), Chile
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S3

Abstracts of the 2023 Annual Meeting of the ALEH

Más datos
Conflict of interest

Yes, Fondecyt # 1241450

Introduction and Objectives

Background: There is limited information on features of lean MASLD patients in Latino subjects. We aimed to analyze the features of MASLD in Chilean patients with normal body mass index (BMI), the frequency of the rs738409 risk polymorphism (PNPLA3 I148M variant) and metabolomic profiles in Chilean individuals with MASLD.

Patients / Materials and Methods

A cross-sectional study involving 181 randomly-selected participants diagnosed with MASLD from the prospective Maule Cohort (BMC Public Health. 2016;16:122). Participants were categorized into lean, overweight, and obese groups based on their BMI. The presence of the rs738409 polymorphism was examined using Sanger sequencing. Metabolomics was assessed using UHPLC-MS in a separate group of biopsy-proven MASLD patients. Statistical analyses of clinical data and genotypes encompassed Fisher's exact test, Chi-square test, Kruskal-Wallis test.

Results and Discussion

31.49% (57) were classified as thin, 36.3% (61) as overweight and 39.8% (67) as obese. Higher ALT levels (p=0.004) and body fat percentage in obese subjects were the only significant differences found among the groups. The allelic frequency of rs738409 was similar among groups 77.1%, 83.6% and 82.5% in lean, overweight, and obese subjects, respectively (n.s.). Circulating metabolome showed increased levels of ceramides in overweight and obese patients compared to lean subjects (p<0.001 for five different species). The increment is higher if all the MASLD patients were considered (Figure). Serum bile acids, particularly chenodeoxycholic acid (p<0.001) and glycochenodeoxycholic acid (p=0.024), were also increased. Lipidomic analysis also showed an increase of polyunsaturated diglyceride and triglyceride species in overweight and obese compared to lean subjects. Among them, most of the species included linoleic acid or alpha-linoleic acid in their esterified chains.

Conclusions

PNPLA3 risk allele was equally frequent in lean and non-lean Chilean MASLD patients. Metabolomic differences were found with non-lean subjects exhibiting higher levels of ceramides and bile acid species compared with lean patients. (Supported by Fondecyt # 1241450)

Texto completo

PNPLA3 I148M frequency and metabolomic profiles in Chilean patients with MASLD

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos